About this document
Adimab Platform Overview Non-Con Q4 2025 by abhi is a document available to read on EtoBox.
Adimab is a leading therapeutic antibody platform founded in 2007, with over 200 unique targets and partnerships with more than 140 pharma/biotech companies. The platform has achieved significant clinical advancements, including 70 programs in humans and 5 approved therapeutics, while continuously evolving through innovative engineering and development processes. Adimab
- Author
- abhi
- Language
- EN